Cargando…
Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells
Targeting inhibitory immune checkpoint molecules has significantly altered cancer treatment regimens. T cell immunoglobulin and mucin domain 3 (TIM3) is one of the major inhibitory immune checkpoints expressed on T cells. Blocking the engagement of TIM3 and its inhibitory ligand galectin-9 may poten...
Autores principales: | Yang, Liu, Chen, Xin, Wang, Qian, Zhu, Yuankui, Wu, Changfa, Ma, Xuqian, Zuo, Dianbao, He, Huixia, Huang, Le, Li, Jingwen, Xia, Chunjiao, Hu, Sheng, Yang, Xiaoqing, Feng, Mingqian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157332/ https://www.ncbi.nlm.nih.gov/pubmed/34079595 http://dx.doi.org/10.3892/ol.2021.12803 |
Ejemplares similares
-
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
por: Chen, Xin, et al.
Publicado: (2020) -
Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma
por: Li, Jingwen, et al.
Publicado: (2022) -
Immune Regulation and Antitumor Effect of TIM-1
por: Du, Peng, et al.
Publicado: (2016) -
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
por: Otáhal, Pavel, et al.
Publicado: (2015) -
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects
por: Kagoya, Yuki, et al.
Publicado: (2018)